NEW YORK (GenomeWeb) – Rosetta Genomics announced today that it has signed a deal under which its full suite of microRNA testing services and molecular diagnostics will be covered by the more than 1,700 payors belonging to America's Choice Provider Network (ACPN).
The arrangement, which also includes offerings from Rosetta's recently acquired PersonalizeDx subsidiary, will make the company's tests and services available to more than 22 million ACPN members.
"With the addition of ACPN to our growing list of established health insurance providers, more than 150 million Americans now have access to our entire suite of high-value diagnostic tests and services," Rosetta President and CEO Kenneth Berlin said in a statement. "This agreement comes at an opportune time, as we see continued growth in collections, including a record month of nearly $1 million in collections last month, along with anticipated increases to reimbursement amounts for some of our key FISH tests."